Accéder au contenu
Merck

Amphiregulin induces human ovarian cancer cell invasion by down-regulating E-cadherin expression.

FEBS letters (2014-09-28)
Wai-Kin So, Qianlan Fan, Man-Tat Lau, Xin Qiu, Jung-Chien Cheng, Peter C K Leung
RÉSUMÉ

Aberrant epidermal growth factor receptor (EGFR) activation is associated with ovarian cancer progression. In this study, we report that the EGFR ligand amphiregulin (AREG) stimulates cell invasion and down-regulates E-cadherin expression in two human ovarian cancer cell lines, SKOV3 and OVCAR5. In addition, AREG increases the expression of transcriptional repressors of E-cadherin including SNAIL, SLUG and ZEB1. siRNA targeting SNAIL or SLUG abolishes AREG-induced cell invasion. Moreover, ERK1/2 and AKT pathways are involved in AREG-induced E-cadherin down-regulation and cell invasion. Finally, we show that three EGFR ligands, AREG, epidermal growth factor (EGF) and transforming growth factor-α (TGF-α), exhibit comparable effects in down-regulating E-cadherin and promoting cell invasion. This study demonstrates that AREG induces ovarian cancer cell invasion by down-regulating E-cadherin expression.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Amphiregulin human, recombinant, expressed in E. coli, lyophilized powder, suitable for cell culture, ≥97% (SDS-PAGE)
Sigma-Aldrich
MISSION® esiRNA, targeting human SNAI1
Sigma-Aldrich
MISSION® esiRNA, targeting mouse Snai1